Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.

Alessandra IurloDaniele CattaneoAlessandra MalatoVincenzo AccursoMario AnnunziataAntonella GozziniAnna Rita ScortechiniCristina BucelliEmilia ScalzulliImma AttolicoAlessandro MaggiBruno MartinoGiovanni CaocciElisabetta AbruzzesePatrizia PregnoLuigiana LucianoMassimo Breccia

Published in: American journal of hematology (2020)

Keyphrases

chronic myeloid leukemia
low dose
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
high dose
patient reported outcomes